SureNano Announces Funding, Debt Settlement and AGSM Results
SureNano Science (OTCQB:SURNF) has announced a recapitalization plan consisting of two key components: a $85,000 debt settlement with insider Charles Malette and a private placement to raise up to $215,000. Both transactions will issue shares at $0.10 per share, totaling up to 3,000,000 shares.
The company also reported results from its August 8, 2025 annual general and special meeting, where 70.29% of shareholders participated. All proposed directors were unanimously elected, Buckley Dodds CPA was appointed as auditor, and the long-term incentive plan was approved. Upon completion of the debt settlement, director Charles Malette will own 34.8% of common shares.
SureNano Science (OTCQB:SURNF) ha annunciato un piano di ricapitalizzazione composto da due elementi principali: un accantonamento del debito di $85.000 con l'insider Charles Malette e un placement privato per raccogliere fino a $215.000. Entrambe le operazioni emetteranno azioni a $0,10 per azione, per un massimo complessivo di 3.000.000 di azioni.
La società ha inoltre comunicato i risultati dell'assemblea generale e straordinaria dell'8 agosto 2025, con la partecipazione del 70,29% degli azionisti. Tutti i direttori proposti sono stati eletti all'unanimità, Buckley Dodds CPA è stato nominato revisore e il piano di incentivazione a lungo termine è stato approvato. Al completamento dell'accantonamento del debito, il direttore Charles Malette deterrà il 34,8% delle azioni ordinarie.
SureNano Science (OTCQB:SURNF) anunció un plan de recapitalización formado por dos componentes clave: una liquidación de deuda de $85,000 con el insider Charles Malette y una colocación privada para recaudar hasta $215,000. Ambas transacciones emitirán acciones a $0.10 por acción, hasta un total de 3,000,000 de acciones.
La compañía también informó los resultados de su junta general anual y extraordinaria del 8 de agosto de 2025, con la participación del 70.29% de los accionistas. Todos los directores propuestos fueron elegidos por unanimidad, Buckley Dodds CPA fue designado auditor y se aprobó el plan de incentivos a largo plazo. Al completarse la liquidación de la deuda, el director Charles Malette poseerá el 34.8% de las acciones ordinarias.
SureNano Science (OTCQB:SURNF)는 두 가지 주요 항목으로 구성된 재자본화 계획을 발표했습니다: 내부자 Charles Malette와의 $85,000 채무 정리와 최대 $215,000을 조달하는 사모 발행입니다. 두 거래 모두
회사는 또한 2025년 8월 8일 연례 및 특별 주주총회 결과를 보고했으며, 주주 70.29%가 참여했습니다. 제안된 모든 이사가 만장일치로 선임되었고, Buckley Dodds CPA가 감사인으로 임명되었으며 장기 인센티브 계획이 승인되었습니다. 채무 정리가 완료되면 이사 Charles Malette는 보통주 34.8%를 보유하게 됩니다.
SureNano Science (OTCQB:SURNF) a annoncé un plan de recapitalisation composé de deux volets principaux : un rachat de dette de 85 000 $ avec l'insider Charles Malette et une augmentation de capital privée visant à lever jusqu'à 215 000 $. Les deux opérations émettront des actions à 0,10 $ par action, pour un total maximal de 3 000 000 d'actions.
La société a également communiqué les résultats de son assemblée générale ordinaire et extraordinaire du 8 août 2025, à laquelle 70,29 % des actionnaires ont participé. Tous les administrateurs proposés ont été élus à l'unanimité, Buckley Dodds CPA a été nommé auditeur et le plan d'incitation à long terme a été approuvé. Une fois le rachat de dette finalisé, l'administrateur Charles Malette détientra 34,8 % des actions ordinaires.
SureNano Science (OTCQB:SURNF) hat einen Rekapitalisierungsplan mit zwei Hauptbestandteilen angekündigt: eine Schuldenbereinigung in Höhe von $85.000 mit dem Insider Charles Malette und eine Privatplatzierung zur Mittelbeschaffung von bis zu $215.000. Beide Transaktionen werden Aktien zu $0,10 je Aktie ausgeben, insgesamt bis zu 3.000.000 Aktien.
Das Unternehmen berichtete außerdem über die Ergebnisse seiner jährlichen und außerordentlichen Hauptversammlung am 8. August 2025, an der 70,29% der Aktionäre teilnahmen. Alle vorgeschlagenen Direktoren wurden einstimmig gewählt, Buckley Dodds CPA wurde zum Prüfer bestellt und der langfristige Anreizplan wurde genehmigt. Nach Abschluss der Schuldenbereinigung wird Direktor Charles Malette 34,8% der Stammaktien halten.
- Successful debt settlement of $85,000 improves balance sheet
- Additional funding of up to $215,000 through private placement
- Strong shareholder participation of 70.29% at AGSM
- Unanimous approval of all proposed corporate actions
- Significant share dilution with 3,000,000 new shares being issued
- Increased insider control with director owning 34.8% post-transaction
- Funds primarily used for operating expenses rather than growth initiatives
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a recapitalization consisting of a debt settlement with an insider for
The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. All securities issued in the private placement will be subject to a four month and a day hold period.
The Company also announces that it held its annual general and special meeting (the "AGSM") held on August 8, 2025. A total of 10 shareholders voted, in person or by proxy, representing a total of 15,083,100 common shares and
All of the voting shareholders unanimously elected each of the four directors standing for election. The voting shareholders unanimously appointed Buckley Dodds CPA as the auditors for the Company and approved the omnibus long-term incentive plan of the Company.
The Debt Settlement is with a related party, director Charles Malette, but is exempt from valuation and minority shareholder approval requirements under NI 61-101 on account of being an amount less than
About SureNano Science Ltd.:
The business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNanoTM surfactant within Canada; Oklahoma, USA; and Colorado, USA.
ON BEHALF OF SURENANO SCIENCE LTD.
"Charles MaLette"
CEO, President, Director & Secretary
T: 604-428-5171
E: info@surenano.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of SureNano. Forward-looking information is based on certain key expectations and assumptions made by the management of SureNano. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although SureNano believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because SureNano can give no assurance that they will prove to be correct.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263465
FAQ
What is the price per share for SureNano's (SURNF) private placement and debt settlement?
How much funding is SureNano (SURNF) raising through its private placement?
What percentage of SureNano (SURNF) will Charles Malette own after the debt settlement?
What was the shareholder participation rate at SureNano's (SURNF) 2025 AGSM?
How will SureNano (SURNF) use the proceeds from the private placement?
